<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643968</url>
  </required_header>
  <id_info>
    <org_study_id>GS-FR-104-1016</org_study_id>
    <nct_id>NCT00643968</nct_id>
  </id_info>
  <brief_title>Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial</brief_title>
  <acronym>COOL</acronym>
  <official_title>Randomized Multicenter Open-Label, Pilot Trial to Evaluate the Efficacy and Safety of Switching HIV-1 Stable Infected Patients Under HAART to a New Once Daily Triple Therapy Combination Including EFV+3TC+TDF Versus a Dual QD Therapy Containing EFV+TDF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain
      plasma HIV-1 RNA BLQ (&lt; 50 copies/mL) (c/mL) at 48 weeks (W48)

      Main Secondary objectives:

      Comparison of the two arms for genotypic resistance profile in case of virological failure

      CD4 changes from baseline

      Evolution of the lipid profile and morphological changes in fat distribution, and safety

      Efficacy and genotypic profile data, results of lipid markers, morphological changes and main
      biological parameters
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (&lt; 50 copies/mL) (c/mL) at 48 weeks (W48)</measure>
    <time_frame>48 wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the two arms for genotypic resistance profile in case of virological failure</measure>
    <time_frame>48 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 changes from baseline</measure>
    <time_frame>48 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the lipid profile and morphological changes in fat distribution, and safety</measure>
    <time_frame>48 wks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF+EFV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF+3TC+EFV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV+TDF</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV+3TC+TDF</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable HAART ≥ 3 months

          -  HIV-1 RNA &lt; 50 c/mL ≥ 6 months

          -  No HAART failure history

        Exclusion Criteria:

          -  Weight &gt; 45 kg

          -  No CD4+ cell count criteria

          -  No significant laboratory or clinical abnormalities

          -  Creatinine Clearance &gt; 60 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Trylesinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>France and French West Indies</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>June 27, 2008</last_update_submitted>
  <last_update_submitted_qc>June 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Aldo Trylesinski- Gilead Sciences</name_title>
    <organization>Gilead Sciences, Inc.</organization>
  </responsible_party>
  <keyword>HIV virological control</keyword>
  <keyword>Lipid profile and morphological fat distribution</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

